Monitoring of 5% Treatment Naïve Intravenous Immunoglobulin (IVIg) Primary Immunodeficiency Disease (PIDD) Patients Using the CareExchange® System: A Pilot Study Using 5% Gammaplex® IVIg in the Home Setting
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
BriovaRx Infusion Services
With
Bio Products Laboratory
Age
15–85
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of any form of Primary Immunodeficiency Disease
Males and Females
≥ 15 and ≤ 85 years of age
5% treatment Naïve IVIg for the treatment of PIDD
Ability to have Gammaplex® IVIg prescribed under the discretion of the patient's treating physician in accordance with standard treatment practices for the entire duration of the study
Ability and willingness to provide informed consent and comply with study requirements and procedures
Ability to read and write English
Understanding of study procedures and ability to comply with study procedures for the entire length of the study
Eligible for infusion services by AxelaCare Health Solutions, LLC, in collaboration with the subject's prescribing physician and insurance provider
You may not be if
The presence of any medical condition that the investigator and/or prescribing physician deems incompatible with participation in this trial.
Prisoners, and other wards of the state
Determined to have non-competency of data collection requirements (physical assessments and use of an iPAD™) by either the home infusion nurse and/or Caregiver.
Receiving Subcutaneous Immunoglobulin (SCIg) Therapy during study participation.
